nodes	percent_of_prediction	percent_of_DWPC	metapath
Alfuzosin—Influenza like illness—Sorafenib—liver cancer	0.0185	0.0203	CcSEcCtD
Alfuzosin—Neuropathy—Sorafenib—liver cancer	0.0179	0.0196	CcSEcCtD
Alfuzosin—Abdominal pain upper—Sorafenib—liver cancer	0.0126	0.0138	CcSEcCtD
Alfuzosin—Breast disorder—Sorafenib—liver cancer	0.0125	0.0137	CcSEcCtD
Alfuzosin—Toxic epidermal necrolysis—Sorafenib—liver cancer	0.0124	0.0136	CcSEcCtD
Alfuzosin—Erectile dysfunction—Sorafenib—liver cancer	0.011	0.0121	CcSEcCtD
Alfuzosin—Infestation—Sorafenib—liver cancer	0.0106	0.0117	CcSEcCtD
Alfuzosin—Infestation NOS—Sorafenib—liver cancer	0.0106	0.0117	CcSEcCtD
Alfuzosin—Neuropathy peripheral—Sorafenib—liver cancer	0.0104	0.0114	CcSEcCtD
Alfuzosin—Jaundice—Sorafenib—liver cancer	0.0104	0.0114	CcSEcCtD
Alfuzosin—Neuralgia—Epirubicin—liver cancer	0.0101	0.0111	CcSEcCtD
Alfuzosin—Hepatobiliary disease—Sorafenib—liver cancer	0.0101	0.011	CcSEcCtD
Alfuzosin—Laryngitis—Epirubicin—liver cancer	0.00975	0.0107	CcSEcCtD
Alfuzosin—Ventricular arrhythmia—Epirubicin—liver cancer	0.0095	0.0104	CcSEcCtD
Alfuzosin—Urinary tract disorder—Sorafenib—liver cancer	0.00943	0.0104	CcSEcCtD
Alfuzosin—Connective tissue disorder—Sorafenib—liver cancer	0.00939	0.0103	CcSEcCtD
Alfuzosin—Urethral disorder—Sorafenib—liver cancer	0.00937	0.0103	CcSEcCtD
Alfuzosin—Neuralgia—Doxorubicin—liver cancer	0.00936	0.0103	CcSEcCtD
Alfuzosin—Laryngitis—Doxorubicin—liver cancer	0.00903	0.00991	CcSEcCtD
Alfuzosin—Flushing—Sorafenib—liver cancer	0.00887	0.00973	CcSEcCtD
Alfuzosin—Cardiac disorder—Sorafenib—liver cancer	0.00887	0.00973	CcSEcCtD
Alfuzosin—Ventricular arrhythmia—Doxorubicin—liver cancer	0.00879	0.00965	CcSEcCtD
Alfuzosin—Angiopathy—Sorafenib—liver cancer	0.00867	0.00951	CcSEcCtD
Alfuzosin—Mediastinal disorder—Sorafenib—liver cancer	0.00861	0.00945	CcSEcCtD
Alfuzosin—Mental disorder—Sorafenib—liver cancer	0.00837	0.00919	CcSEcCtD
Alfuzosin—Liver injury—Epirubicin—liver cancer	0.00836	0.00917	CcSEcCtD
Alfuzosin—Cardiovascular disorder—Epirubicin—liver cancer	0.008	0.00878	CcSEcCtD
Alfuzosin—Prazosin—CYP1A1—liver cancer	0.00796	1	CrCbGaD
Alfuzosin—Arthropathy—Epirubicin—liver cancer	0.00773	0.00849	CcSEcCtD
Alfuzosin—Liver injury—Doxorubicin—liver cancer	0.00773	0.00848	CcSEcCtD
Alfuzosin—Angioedema—Sorafenib—liver cancer	0.0076	0.00834	CcSEcCtD
Alfuzosin—Syncope—Sorafenib—liver cancer	0.00746	0.00818	CcSEcCtD
Alfuzosin—Cardiovascular disorder—Doxorubicin—liver cancer	0.0074	0.00813	CcSEcCtD
Alfuzosin—Loss of consciousness—Sorafenib—liver cancer	0.00731	0.00802	CcSEcCtD
Alfuzosin—Arthropathy—Doxorubicin—liver cancer	0.00715	0.00785	CcSEcCtD
Alfuzosin—Arthralgia—Sorafenib—liver cancer	0.00708	0.00777	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00703	0.00772	CcSEcCtD
Alfuzosin—Hepatocellular injury—Epirubicin—liver cancer	0.00703	0.00772	CcSEcCtD
Alfuzosin—Ventricular tachycardia—Epirubicin—liver cancer	0.00703	0.00772	CcSEcCtD
Alfuzosin—Dry mouth—Sorafenib—liver cancer	0.00692	0.0076	CcSEcCtD
Alfuzosin—Influenza like illness—Epirubicin—liver cancer	0.00683	0.00749	CcSEcCtD
Alfuzosin—Infection—Sorafenib—liver cancer	0.00674	0.0074	CcSEcCtD
Alfuzosin—Shock—Sorafenib—liver cancer	0.00668	0.00733	CcSEcCtD
Alfuzosin—Nervous system disorder—Sorafenib—liver cancer	0.00666	0.0073	CcSEcCtD
Alfuzosin—Thrombocytopenia—Sorafenib—liver cancer	0.00665	0.00729	CcSEcCtD
Alfuzosin—Neuropathy—Epirubicin—liver cancer	0.0066	0.00724	CcSEcCtD
Alfuzosin—Skin disorder—Sorafenib—liver cancer	0.00659	0.00724	CcSEcCtD
Alfuzosin—Ventricular tachycardia—Doxorubicin—liver cancer	0.00651	0.00714	CcSEcCtD
Alfuzosin—Hepatocellular injury—Doxorubicin—liver cancer	0.00651	0.00714	CcSEcCtD
Alfuzosin—Influenza like illness—Doxorubicin—liver cancer	0.00632	0.00693	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00618	0.00679	CcSEcCtD
Alfuzosin—Neuropathy—Doxorubicin—liver cancer	0.00611	0.0067	CcSEcCtD
Alfuzosin—Dyspepsia—Sorafenib—liver cancer	0.00597	0.00656	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Sorafenib—liver cancer	0.00586	0.00643	CcSEcCtD
Alfuzosin—Fatigue—Sorafenib—liver cancer	0.00585	0.00642	CcSEcCtD
Alfuzosin—Pain—Sorafenib—liver cancer	0.0058	0.00637	CcSEcCtD
Alfuzosin—Constipation—Sorafenib—liver cancer	0.0058	0.00637	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Sorafenib—liver cancer	0.00555	0.00609	CcSEcCtD
Alfuzosin—Urticaria—Sorafenib—liver cancer	0.00539	0.00592	CcSEcCtD
Alfuzosin—Abdominal pain—Sorafenib—liver cancer	0.00537	0.00589	CcSEcCtD
Alfuzosin—Osteoarthritis—Epirubicin—liver cancer	0.0051	0.0056	CcSEcCtD
Alfuzosin—Asthenia—Sorafenib—liver cancer	0.00487	0.00534	CcSEcCtD
Alfuzosin—Pruritus—Sorafenib—liver cancer	0.0048	0.00527	CcSEcCtD
Alfuzosin—Osteoarthritis—Doxorubicin—liver cancer	0.00472	0.00518	CcSEcCtD
Alfuzosin—Abdominal pain upper—Epirubicin—liver cancer	0.00466	0.00512	CcSEcCtD
Alfuzosin—Orthostatic hypotension—Epirubicin—liver cancer	0.00466	0.00512	CcSEcCtD
Alfuzosin—Diarrhoea—Sorafenib—liver cancer	0.00464	0.0051	CcSEcCtD
Alfuzosin—Breast disorder—Epirubicin—liver cancer	0.00461	0.00506	CcSEcCtD
Alfuzosin—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.0046	0.00504	CcSEcCtD
Alfuzosin—Dizziness—Sorafenib—liver cancer	0.00449	0.00493	CcSEcCtD
Alfuzosin—Vomiting—Sorafenib—liver cancer	0.00432	0.00474	CcSEcCtD
Alfuzosin—Abdominal pain upper—Doxorubicin—liver cancer	0.00431	0.00473	CcSEcCtD
Alfuzosin—Orthostatic hypotension—Doxorubicin—liver cancer	0.00431	0.00473	CcSEcCtD
Alfuzosin—Angina pectoris—Epirubicin—liver cancer	0.0043	0.00472	CcSEcCtD
Alfuzosin—Rash—Sorafenib—liver cancer	0.00428	0.0047	CcSEcCtD
Alfuzosin—Dermatitis—Sorafenib—liver cancer	0.00428	0.00469	CcSEcCtD
Alfuzosin—Breast disorder—Doxorubicin—liver cancer	0.00427	0.00468	CcSEcCtD
Alfuzosin—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.00425	0.00467	CcSEcCtD
Alfuzosin—Headache—Sorafenib—liver cancer	0.00425	0.00467	CcSEcCtD
Alfuzosin—Bronchitis—Epirubicin—liver cancer	0.00424	0.00466	CcSEcCtD
Alfuzosin—Upper respiratory tract infection—Epirubicin—liver cancer	0.0041	0.0045	CcSEcCtD
Alfuzosin—Nausea—Sorafenib—liver cancer	0.00403	0.00442	CcSEcCtD
Alfuzosin—Angina pectoris—Doxorubicin—liver cancer	0.00398	0.00436	CcSEcCtD
Alfuzosin—Infestation NOS—Epirubicin—liver cancer	0.00393	0.00432	CcSEcCtD
Alfuzosin—Infestation—Epirubicin—liver cancer	0.00393	0.00432	CcSEcCtD
Alfuzosin—Drowsiness—Epirubicin—liver cancer	0.00393	0.00432	CcSEcCtD
Alfuzosin—Bronchitis—Doxorubicin—liver cancer	0.00393	0.00431	CcSEcCtD
Alfuzosin—Neuropathy peripheral—Epirubicin—liver cancer	0.00386	0.00423	CcSEcCtD
Alfuzosin—Jaundice—Epirubicin—liver cancer	0.00383	0.00421	CcSEcCtD
Alfuzosin—Upper respiratory tract infection—Doxorubicin—liver cancer	0.00379	0.00416	CcSEcCtD
Alfuzosin—Sweating—Epirubicin—liver cancer	0.00377	0.00414	CcSEcCtD
Alfuzosin—Hepatobiliary disease—Epirubicin—liver cancer	0.00372	0.00408	CcSEcCtD
Alfuzosin—Sinusitis—Epirubicin—liver cancer	0.00369	0.00405	CcSEcCtD
Alfuzosin—Infestation NOS—Doxorubicin—liver cancer	0.00364	0.00399	CcSEcCtD
Alfuzosin—Drowsiness—Doxorubicin—liver cancer	0.00364	0.00399	CcSEcCtD
Alfuzosin—Infestation—Doxorubicin—liver cancer	0.00364	0.00399	CcSEcCtD
Alfuzosin—Neuropathy peripheral—Doxorubicin—liver cancer	0.00357	0.00391	CcSEcCtD
Alfuzosin—Jaundice—Doxorubicin—liver cancer	0.00355	0.00389	CcSEcCtD
Alfuzosin—Rhinitis—Epirubicin—liver cancer	0.00354	0.00388	CcSEcCtD
Alfuzosin—Pharyngitis—Epirubicin—liver cancer	0.0035	0.00385	CcSEcCtD
Alfuzosin—Sweating—Doxorubicin—liver cancer	0.00349	0.00383	CcSEcCtD
Alfuzosin—Urinary tract disorder—Epirubicin—liver cancer	0.00349	0.00383	CcSEcCtD
Alfuzosin—Connective tissue disorder—Epirubicin—liver cancer	0.00347	0.00381	CcSEcCtD
Alfuzosin—Urethral disorder—Epirubicin—liver cancer	0.00346	0.0038	CcSEcCtD
Alfuzosin—Hepatobiliary disease—Doxorubicin—liver cancer	0.00344	0.00378	CcSEcCtD
Alfuzosin—Sinusitis—Doxorubicin—liver cancer	0.00341	0.00375	CcSEcCtD
Alfuzosin—Eye disorder—Epirubicin—liver cancer	0.0033	0.00362	CcSEcCtD
Alfuzosin—Flushing—Epirubicin—liver cancer	0.00328	0.0036	CcSEcCtD
Alfuzosin—Cardiac disorder—Epirubicin—liver cancer	0.00328	0.0036	CcSEcCtD
Alfuzosin—Rhinitis—Doxorubicin—liver cancer	0.00328	0.00359	CcSEcCtD
Alfuzosin—Pharyngitis—Doxorubicin—liver cancer	0.00324	0.00356	CcSEcCtD
Alfuzosin—Urinary tract disorder—Doxorubicin—liver cancer	0.00323	0.00354	CcSEcCtD
Alfuzosin—Connective tissue disorder—Doxorubicin—liver cancer	0.00321	0.00352	CcSEcCtD
Alfuzosin—Angiopathy—Epirubicin—liver cancer	0.0032	0.00352	CcSEcCtD
Alfuzosin—Urethral disorder—Doxorubicin—liver cancer	0.0032	0.00351	CcSEcCtD
Alfuzosin—Mediastinal disorder—Epirubicin—liver cancer	0.00318	0.00349	CcSEcCtD
Alfuzosin—Mental disorder—Epirubicin—liver cancer	0.00309	0.00339	CcSEcCtD
Alfuzosin—Eye disorder—Doxorubicin—liver cancer	0.00305	0.00335	CcSEcCtD
Alfuzosin—Flushing—Doxorubicin—liver cancer	0.00303	0.00333	CcSEcCtD
Alfuzosin—Cardiac disorder—Doxorubicin—liver cancer	0.00303	0.00333	CcSEcCtD
Alfuzosin—Back pain—Epirubicin—liver cancer	0.00297	0.00326	CcSEcCtD
Alfuzosin—Angiopathy—Doxorubicin—liver cancer	0.00296	0.00325	CcSEcCtD
Alfuzosin—Mediastinal disorder—Doxorubicin—liver cancer	0.00294	0.00323	CcSEcCtD
Alfuzosin—Mental disorder—Doxorubicin—liver cancer	0.00286	0.00314	CcSEcCtD
Alfuzosin—Ill-defined disorder—Epirubicin—liver cancer	0.00285	0.00313	CcSEcCtD
Alfuzosin—Malaise—Epirubicin—liver cancer	0.00277	0.00304	CcSEcCtD
Alfuzosin—Vertigo—Epirubicin—liver cancer	0.00276	0.00303	CcSEcCtD
Alfuzosin—Syncope—Epirubicin—liver cancer	0.00276	0.00302	CcSEcCtD
Alfuzosin—Back pain—Doxorubicin—liver cancer	0.00275	0.00302	CcSEcCtD
Alfuzosin—Palpitations—Epirubicin—liver cancer	0.00272	0.00298	CcSEcCtD
Alfuzosin—Loss of consciousness—Epirubicin—liver cancer	0.0027	0.00296	CcSEcCtD
Alfuzosin—Ill-defined disorder—Doxorubicin—liver cancer	0.00264	0.0029	CcSEcCtD
Alfuzosin—Arthralgia—Epirubicin—liver cancer	0.00262	0.00287	CcSEcCtD
Alfuzosin—Chest pain—Epirubicin—liver cancer	0.00262	0.00287	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.0026	0.00285	CcSEcCtD
Alfuzosin—Discomfort—Epirubicin—liver cancer	0.00259	0.00284	CcSEcCtD
Alfuzosin—Malaise—Doxorubicin—liver cancer	0.00256	0.00281	CcSEcCtD
Alfuzosin—Dry mouth—Epirubicin—liver cancer	0.00256	0.00281	CcSEcCtD
Alfuzosin—Vertigo—Doxorubicin—liver cancer	0.00256	0.0028	CcSEcCtD
Alfuzosin—Syncope—Doxorubicin—liver cancer	0.00255	0.0028	CcSEcCtD
Alfuzosin—Palpitations—Doxorubicin—liver cancer	0.00251	0.00276	CcSEcCtD
Alfuzosin—Oedema—Epirubicin—liver cancer	0.00251	0.00275	CcSEcCtD
Alfuzosin—Loss of consciousness—Doxorubicin—liver cancer	0.0025	0.00274	CcSEcCtD
Alfuzosin—Infection—Epirubicin—liver cancer	0.00249	0.00273	CcSEcCtD
Alfuzosin—Shock—Epirubicin—liver cancer	0.00247	0.00271	CcSEcCtD
Alfuzosin—Nervous system disorder—Epirubicin—liver cancer	0.00246	0.0027	CcSEcCtD
Alfuzosin—Thrombocytopenia—Epirubicin—liver cancer	0.00246	0.0027	CcSEcCtD
Alfuzosin—Tachycardia—Epirubicin—liver cancer	0.00245	0.00269	CcSEcCtD
Alfuzosin—Skin disorder—Epirubicin—liver cancer	0.00244	0.00267	CcSEcCtD
Alfuzosin—Hyperhidrosis—Epirubicin—liver cancer	0.00242	0.00266	CcSEcCtD
Alfuzosin—Arthralgia—Doxorubicin—liver cancer	0.00242	0.00266	CcSEcCtD
Alfuzosin—Chest pain—Doxorubicin—liver cancer	0.00242	0.00266	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.0024	0.00264	CcSEcCtD
Alfuzosin—Discomfort—Doxorubicin—liver cancer	0.00239	0.00263	CcSEcCtD
Alfuzosin—Dry mouth—Doxorubicin—liver cancer	0.00237	0.0026	CcSEcCtD
Alfuzosin—Hypotension—Epirubicin—liver cancer	0.00234	0.00257	CcSEcCtD
Alfuzosin—Oedema—Doxorubicin—liver cancer	0.00232	0.00255	CcSEcCtD
Alfuzosin—Infection—Doxorubicin—liver cancer	0.00231	0.00253	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00229	0.00251	CcSEcCtD
Alfuzosin—Shock—Doxorubicin—liver cancer	0.00228	0.00251	CcSEcCtD
Alfuzosin—Nervous system disorder—Doxorubicin—liver cancer	0.00228	0.0025	CcSEcCtD
Alfuzosin—Thrombocytopenia—Doxorubicin—liver cancer	0.00227	0.00249	CcSEcCtD
Alfuzosin—Tachycardia—Doxorubicin—liver cancer	0.00227	0.00249	CcSEcCtD
Alfuzosin—Skin disorder—Doxorubicin—liver cancer	0.00225	0.00247	CcSEcCtD
Alfuzosin—Hyperhidrosis—Doxorubicin—liver cancer	0.00224	0.00246	CcSEcCtD
Alfuzosin—Somnolence—Epirubicin—liver cancer	0.00223	0.00245	CcSEcCtD
Alfuzosin—Dyspepsia—Epirubicin—liver cancer	0.00221	0.00242	CcSEcCtD
Alfuzosin—Hypotension—Doxorubicin—liver cancer	0.00217	0.00238	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Epirubicin—liver cancer	0.00217	0.00238	CcSEcCtD
Alfuzosin—Fatigue—Epirubicin—liver cancer	0.00216	0.00237	CcSEcCtD
Alfuzosin—Pain—Epirubicin—liver cancer	0.00215	0.00235	CcSEcCtD
Alfuzosin—Constipation—Epirubicin—liver cancer	0.00215	0.00235	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00211	0.00232	CcSEcCtD
Alfuzosin—Feeling abnormal—Epirubicin—liver cancer	0.00207	0.00227	CcSEcCtD
Alfuzosin—Somnolence—Doxorubicin—liver cancer	0.00206	0.00226	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Epirubicin—liver cancer	0.00205	0.00225	CcSEcCtD
Alfuzosin—Dyspepsia—Doxorubicin—liver cancer	0.00204	0.00224	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Doxorubicin—liver cancer	0.002	0.0022	CcSEcCtD
Alfuzosin—Fatigue—Doxorubicin—liver cancer	0.002	0.0022	CcSEcCtD
Alfuzosin—Urticaria—Epirubicin—liver cancer	0.00199	0.00219	CcSEcCtD
Alfuzosin—Pain—Doxorubicin—liver cancer	0.00198	0.00218	CcSEcCtD
Alfuzosin—Constipation—Doxorubicin—liver cancer	0.00198	0.00218	CcSEcCtD
Alfuzosin—Abdominal pain—Epirubicin—liver cancer	0.00198	0.00218	CcSEcCtD
Alfuzosin—Feeling abnormal—Doxorubicin—liver cancer	0.00191	0.0021	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Doxorubicin—liver cancer	0.0019	0.00208	CcSEcCtD
Alfuzosin—Urticaria—Doxorubicin—liver cancer	0.00184	0.00202	CcSEcCtD
Alfuzosin—Abdominal pain—Doxorubicin—liver cancer	0.00183	0.00201	CcSEcCtD
Alfuzosin—Asthenia—Epirubicin—liver cancer	0.0018	0.00198	CcSEcCtD
Alfuzosin—Pruritus—Epirubicin—liver cancer	0.00177	0.00195	CcSEcCtD
Alfuzosin—Diarrhoea—Epirubicin—liver cancer	0.00172	0.00188	CcSEcCtD
Alfuzosin—Asthenia—Doxorubicin—liver cancer	0.00167	0.00183	CcSEcCtD
Alfuzosin—Dizziness—Epirubicin—liver cancer	0.00166	0.00182	CcSEcCtD
Alfuzosin—Pruritus—Doxorubicin—liver cancer	0.00164	0.0018	CcSEcCtD
Alfuzosin—Vomiting—Epirubicin—liver cancer	0.00159	0.00175	CcSEcCtD
Alfuzosin—Diarrhoea—Doxorubicin—liver cancer	0.00159	0.00174	CcSEcCtD
Alfuzosin—Rash—Epirubicin—liver cancer	0.00158	0.00174	CcSEcCtD
Alfuzosin—Dermatitis—Epirubicin—liver cancer	0.00158	0.00173	CcSEcCtD
Alfuzosin—Headache—Epirubicin—liver cancer	0.00157	0.00172	CcSEcCtD
Alfuzosin—Dizziness—Doxorubicin—liver cancer	0.00153	0.00168	CcSEcCtD
Alfuzosin—Nausea—Epirubicin—liver cancer	0.00149	0.00164	CcSEcCtD
Alfuzosin—Vomiting—Doxorubicin—liver cancer	0.00148	0.00162	CcSEcCtD
Alfuzosin—Rash—Doxorubicin—liver cancer	0.00146	0.00161	CcSEcCtD
Alfuzosin—Dermatitis—Doxorubicin—liver cancer	0.00146	0.0016	CcSEcCtD
Alfuzosin—Headache—Doxorubicin—liver cancer	0.00145	0.0016	CcSEcCtD
Alfuzosin—Nausea—Doxorubicin—liver cancer	0.00138	0.00151	CcSEcCtD
Alfuzosin—CYP3A4—Biological oxidations—GSTP1—liver cancer	0.000103	0.00128	CbGpPWpGaD
Alfuzosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—liver cancer	0.000103	0.00127	CbGpPWpGaD
Alfuzosin—CYP3A4—Metapathway biotransformation—GSTP1—liver cancer	0.000102	0.00126	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—F2—liver cancer	9.9e-05	0.00122	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—FST—liver cancer	9.89e-05	0.00122	CbGpPWpGaD
Alfuzosin—KCNH2—Neuronal System—HRAS—liver cancer	9.87e-05	0.00122	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—PRKCE—liver cancer	9.71e-05	0.0012	CbGpPWpGaD
Alfuzosin—CYP3A4—Biological oxidations—GSTM1—liver cancer	9.51e-05	0.00118	CbGpPWpGaD
Alfuzosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—liver cancer	9.46e-05	0.00117	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—TRIO—liver cancer	9.44e-05	0.00117	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—SHC3—liver cancer	9.39e-05	0.00116	CbGpPWpGaD
Alfuzosin—CYP3A4—Metapathway biotransformation—GSTM1—liver cancer	9.38e-05	0.00116	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CCR4—liver cancer	9.05e-05	0.00112	CbGpPWpGaD
Alfuzosin—CYP3A4—Biological oxidations—CYP1A1—liver cancer	9.02e-05	0.00112	CbGpPWpGaD
Alfuzosin—CYP3A4—Metapathway biotransformation—CYP1A1—liver cancer	8.89e-05	0.0011	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—PRKCE—liver cancer	8.82e-05	0.00109	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—F2—liver cancer	8.79e-05	0.00109	CbGpPWpGaD
Alfuzosin—ADRA1B—G alpha (q) signalling events—PIK3CA—liver cancer	8.77e-05	0.00109	CbGpPWpGaD
Alfuzosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—liver cancer	8.75e-05	0.00108	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—CSF2—liver cancer	8.59e-05	0.00106	CbGpPWpGaD
Alfuzosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—liver cancer	8.54e-05	0.00106	CbGpPWpGaD
Alfuzosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—liver cancer	8.37e-05	0.00104	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—FST—liver cancer	8.21e-05	0.00102	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—PRKCE—liver cancer	8.06e-05	0.000997	CbGpPWpGaD
Alfuzosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—liver cancer	7.85e-05	0.000971	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—TRIO—liver cancer	7.83e-05	0.000969	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—CSF2—liver cancer	7.8e-05	0.000965	CbGpPWpGaD
Alfuzosin—ADRA1A—G alpha (q) signalling events—PIK3CA—liver cancer	7.79e-05	0.000964	CbGpPWpGaD
Alfuzosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—liver cancer	7.59e-05	0.000939	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CCR4—liver cancer	7.51e-05	0.000929	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—PRKCE—liver cancer	7.32e-05	0.000905	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—FST—liver cancer	7.29e-05	0.000902	CbGpPWpGaD
Alfuzosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—liver cancer	7.26e-05	0.000898	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—PRKCE—liver cancer	7.16e-05	0.000886	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—ADAM17—liver cancer	7.15e-05	0.000885	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—CSF2—liver cancer	7.13e-05	0.000882	CbGpPWpGaD
Alfuzosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—liver cancer	6.97e-05	0.000862	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—TRIO—liver cancer	6.96e-05	0.000861	CbGpPWpGaD
Alfuzosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—liver cancer	6.95e-05	0.00086	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—UGDH—liver cancer	6.74e-05	0.000834	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—F2—liver cancer	6.74e-05	0.000834	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PSMA4—liver cancer	6.72e-05	0.000832	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PSMD10—liver cancer	6.72e-05	0.000832	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CCR4—liver cancer	6.67e-05	0.000825	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—PRKCE—liver cancer	6.5e-05	0.000804	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—CSF2—liver cancer	6.47e-05	0.000801	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—PIK3CG—liver cancer	6.45e-05	0.000798	CbGpPWpGaD
Alfuzosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—liver cancer	6.45e-05	0.000798	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—EPT1—liver cancer	6.34e-05	0.000784	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—CSF2—liver cancer	6.33e-05	0.000783	CbGpPWpGaD
Alfuzosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—liver cancer	6.17e-05	0.000764	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—F2—liver cancer	6.12e-05	0.000757	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—TAT—liver cancer	6.01e-05	0.000744	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—ADAM17—liver cancer	5.94e-05	0.000734	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—PIK3CG—liver cancer	5.86e-05	0.000725	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—CSF2—liver cancer	5.75e-05	0.000711	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—PIK3CD—liver cancer	5.67e-05	0.000702	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—F2—liver cancer	5.59e-05	0.000692	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PSMA4—liver cancer	5.58e-05	0.00069	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PSMD10—liver cancer	5.58e-05	0.00069	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—PIK3CG—liver cancer	5.35e-05	0.000662	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—ADAM17—liver cancer	5.27e-05	0.000652	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PRKCE—liver cancer	5.21e-05	0.000644	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—PIK3CD—liver cancer	5.15e-05	0.000637	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—F2—liver cancer	5.08e-05	0.000629	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—F2—liver cancer	4.97e-05	0.000615	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PSMA4—liver cancer	4.96e-05	0.000613	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PSMD10—liver cancer	4.96e-05	0.000613	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—PIK3CB—liver cancer	4.94e-05	0.000612	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—IGF2—liver cancer	4.93e-05	0.000611	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—PIK3CG—liver cancer	4.86e-05	0.000601	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—PIK3CG—liver cancer	4.76e-05	0.000588	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—PIK3CD—liver cancer	4.71e-05	0.000582	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CSF2—liver cancer	4.61e-05	0.00057	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—RAF1—liver cancer	4.6e-05	0.000569	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—H2AFX—liver cancer	4.54e-05	0.000562	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—IL2—liver cancer	4.54e-05	0.000562	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—F2—liver cancer	4.51e-05	0.000558	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—PIK3CB—liver cancer	4.49e-05	0.000555	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PRKCE—liver cancer	4.32e-05	0.000535	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—PIK3CG—liver cancer	4.32e-05	0.000534	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—PIK3CD—liver cancer	4.27e-05	0.000529	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—PIK3CD—liver cancer	4.18e-05	0.000517	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—IL2—liver cancer	4.12e-05	0.00051	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—TERT—liver cancer	4.11e-05	0.000508	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—PIK3CB—liver cancer	4.1e-05	0.000508	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—IGF2—liver cancer	4.1e-05	0.000507	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CPT1B—liver cancer	4.09e-05	0.000505	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GLUL—liver cancer	4.09e-05	0.000505	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—NR1H4—liver cancer	3.94e-05	0.000487	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GSTA3—liver cancer	3.87e-05	0.000479	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PRKCE—liver cancer	3.84e-05	0.000475	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CSF2—liver cancer	3.82e-05	0.000473	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—RAF1—liver cancer	3.82e-05	0.000472	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—PIK3CD—liver cancer	3.8e-05	0.00047	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—H2AFX—liver cancer	3.77e-05	0.000466	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—IL2—liver cancer	3.77e-05	0.000466	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—KDR—liver cancer	3.76e-05	0.000465	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—MAPK14—liver cancer	3.73e-05	0.000462	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—PIK3CB—liver cancer	3.73e-05	0.000461	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—ESR1—liver cancer	3.66e-05	0.000453	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—PIK3CB—liver cancer	3.64e-05	0.000451	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—IGF2—liver cancer	3.64e-05	0.00045	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—F2—liver cancer	3.62e-05	0.000447	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GSTA4—liver cancer	3.54e-05	0.000438	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PIK3CG—liver cancer	3.46e-05	0.000428	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—APC—liver cancer	3.46e-05	0.000428	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GSTA2—liver cancer	3.45e-05	0.000427	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—IL2—liver cancer	3.42e-05	0.000423	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—TERT—liver cancer	3.41e-05	0.000422	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CSF2—liver cancer	3.4e-05	0.00042	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—RAF1—liver cancer	3.39e-05	0.000419	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—H2AFX—liver cancer	3.35e-05	0.000414	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—IL2—liver cancer	3.35e-05	0.000414	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GSTA1—liver cancer	3.33e-05	0.000412	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—PIK3CB—liver cancer	3.31e-05	0.000409	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—NAT2—liver cancer	3.29e-05	0.000407	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—BRAF—liver cancer	3.25e-05	0.000402	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ALDOB—liver cancer	3.16e-05	0.000391	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—KDR—liver cancer	3.12e-05	0.000386	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—MAPK14—liver cancer	3.1e-05	0.000383	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PIK3CD—liver cancer	3.04e-05	0.000376	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—IL2—liver cancer	3.04e-05	0.000376	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—ESR1—liver cancer	3.04e-05	0.000376	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—TERT—liver cancer	3.03e-05	0.000375	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—PIK3CA—liver cancer	3.01e-05	0.000373	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CRABP1—liver cancer	3.01e-05	0.000373	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—SERPINE1—liver cancer	3.01e-05	0.000372	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—F2—liver cancer	3e-05	0.000371	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—KRAS—liver cancer	2.98e-05	0.000368	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PIK3CG—liver cancer	2.87e-05	0.000355	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—APC—liver cancer	2.87e-05	0.000355	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—KDR—liver cancer	2.77e-05	0.000343	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—MAPK14—liver cancer	2.75e-05	0.00034	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—PIK3CA—liver cancer	2.74e-05	0.000339	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—RAF1—liver cancer	2.72e-05	0.000336	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—BRAF—liver cancer	2.7e-05	0.000334	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—ESR1—liver cancer	2.7e-05	0.000334	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—F2—liver cancer	2.67e-05	0.00033	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—MTOR—liver cancer	2.65e-05	0.000328	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PIK3CB—liver cancer	2.65e-05	0.000328	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—HPGDS—liver cancer	2.63e-05	0.000326	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—APC—liver cancer	2.55e-05	0.000316	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PIK3CG—liver cancer	2.55e-05	0.000316	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—HRAS—liver cancer	2.53e-05	0.000313	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PIK3CD—liver cancer	2.52e-05	0.000312	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—PIK3CA—liver cancer	2.5e-05	0.000309	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—SERPINE1—liver cancer	2.5e-05	0.000309	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CDKN1B—liver cancer	2.49e-05	0.000308	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—KRAS—liver cancer	2.47e-05	0.000306	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—AKT1—liver cancer	2.46e-05	0.000305	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CASP3—liver cancer	2.44e-05	0.000302	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—IL2—liver cancer	2.44e-05	0.000301	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—IL6—liver cancer	2.42e-05	0.0003	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—BRAF—liver cancer	2.4e-05	0.000297	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CCND1—liver cancer	2.37e-05	0.000294	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—JUN—liver cancer	2.37e-05	0.000293	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CTNNB1—liver cancer	2.35e-05	0.000291	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PSMD10—liver cancer	2.35e-05	0.00029	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PSMA4—liver cancer	2.35e-05	0.00029	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—MMP9—liver cancer	2.3e-05	0.000285	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CDKN1A—liver cancer	2.3e-05	0.000284	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GOT2—liver cancer	2.28e-05	0.000282	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—PIK3CA—liver cancer	2.27e-05	0.000281	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—RAF1—liver cancer	2.25e-05	0.000279	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PIK3CD—liver cancer	2.24e-05	0.000277	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—MAPK8—liver cancer	2.24e-05	0.000277	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—AKT1—liver cancer	2.24e-05	0.000277	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—PIK3CA—liver cancer	2.22e-05	0.000275	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—SERPINE1—liver cancer	2.22e-05	0.000274	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—MTOR—liver cancer	2.2e-05	0.000272	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PIK3CB—liver cancer	2.2e-05	0.000272	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—KRAS—liver cancer	2.2e-05	0.000272	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CYP2E1—liver cancer	2.15e-05	0.000266	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—HRAS—liver cancer	2.1e-05	0.00026	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—VEGFA—liver cancer	2.07e-05	0.000256	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CDKN1B—liver cancer	2.07e-05	0.000256	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—STAT3—liver cancer	2.05e-05	0.000254	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—AKT1—liver cancer	2.04e-05	0.000253	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CASP3—liver cancer	2.02e-05	0.00025	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—IL2—liver cancer	2.02e-05	0.00025	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—PIK3CA—liver cancer	2.02e-05	0.00025	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—IL6—liver cancer	2.01e-05	0.000249	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CYCS—liver cancer	2.01e-05	0.000248	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—RAF1—liver cancer	2e-05	0.000248	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GGT1—liver cancer	1.97e-05	0.000244	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GOT1—liver cancer	1.97e-05	0.000244	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CCND1—liver cancer	1.97e-05	0.000244	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—JUN—liver cancer	1.97e-05	0.000243	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PIK3CB—liver cancer	1.95e-05	0.000242	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—MTOR—liver cancer	1.95e-05	0.000242	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CTNNB1—liver cancer	1.95e-05	0.000241	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—MMP9—liver cancer	1.91e-05	0.000237	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CDKN1A—liver cancer	1.91e-05	0.000236	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—MYC—liver cancer	1.9e-05	0.000236	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—TGFB1—liver cancer	1.9e-05	0.000235	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—HRAS—liver cancer	1.87e-05	0.000231	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—MAPK8—liver cancer	1.86e-05	0.00023	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—AKT1—liver cancer	1.86e-05	0.00023	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CDKN1B—liver cancer	1.83e-05	0.000227	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—AKT1—liver cancer	1.81e-05	0.000225	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CASP3—liver cancer	1.8e-05	0.000222	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—IL2—liver cancer	1.8e-05	0.000222	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—IL6—liver cancer	1.79e-05	0.000221	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GSTP1—liver cancer	1.77e-05	0.000219	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—KRAS—liver cancer	1.76e-05	0.000218	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CCND1—liver cancer	1.75e-05	0.000217	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—JUN—liver cancer	1.75e-05	0.000216	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—HMOX1—liver cancer	1.75e-05	0.000216	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CTNNB1—liver cancer	1.73e-05	0.000214	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—VEGFA—liver cancer	1.72e-05	0.000213	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—STAT3—liver cancer	1.7e-05	0.00021	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—MMP9—liver cancer	1.7e-05	0.00021	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CDKN1A—liver cancer	1.69e-05	0.000209	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—MAPK8—liver cancer	1.65e-05	0.000204	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—AKT1—liver cancer	1.65e-05	0.000204	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GSTM1—liver cancer	1.63e-05	0.000201	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PIK3CA—liver cancer	1.62e-05	0.0002	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—MYC—liver cancer	1.58e-05	0.000196	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—TGFB1—liver cancer	1.58e-05	0.000195	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—TP53—liver cancer	1.56e-05	0.000193	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CYP1A1—liver cancer	1.54e-05	0.000191	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—VEGFA—liver cancer	1.53e-05	0.000189	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—STAT3—liver cancer	1.51e-05	0.000187	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—HRAS—liver cancer	1.5e-05	0.000185	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—KRAS—liver cancer	1.46e-05	0.000181	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—MTHFR—liver cancer	1.44e-05	0.000178	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—IL6—liver cancer	1.43e-05	0.000177	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PPARA—liver cancer	1.41e-05	0.000174	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—MYC—liver cancer	1.4e-05	0.000174	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—TGFB1—liver cancer	1.4e-05	0.000173	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PIK3CA—liver cancer	1.34e-05	0.000166	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—AKT1—liver cancer	1.32e-05	0.000163	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—TP53—liver cancer	1.3e-05	0.000161	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—KRAS—liver cancer	1.3e-05	0.00016	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—HRAS—liver cancer	1.24e-05	0.000154	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PIK3CG—liver cancer	1.21e-05	0.000149	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PIK3CA—liver cancer	1.19e-05	0.000147	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—IL6—liver cancer	1.19e-05	0.000147	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PPARG—liver cancer	1.17e-05	0.000144	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—TP53—liver cancer	1.15e-05	0.000143	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—HRAS—liver cancer	1.1e-05	0.000136	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—AKT1—liver cancer	1.1e-05	0.000136	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PIK3CD—liver cancer	1.06e-05	0.000131	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—IL6—liver cancer	1.06e-05	0.000131	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ALB—liver cancer	1.05e-05	0.00013	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—AKT1—liver cancer	9.73e-06	0.00012	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PIK3CB—liver cancer	9.25e-06	0.000114	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PIK3CA—liver cancer	5.64e-06	6.98e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—AKT1—liver cancer	4.61e-06	5.7e-05	CbGpPWpGaD
